ArticlePloS one2011
Dopamine-induced apoptosis of lactotropes is mediated by the short isoform of D2 receptor.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 43 citations in OpenAlex.
- L-Dopa Might Be Insufficient to Suppress Development of Prolactinomas in Dihydropteridine Reductase-Deficiency Patients.JCEM case reports · 2024Article
- The dopaminergic control of Cushing's syndrome.Journal of endocrinological investigation · 2022Review
- Is prolactin receptor signaling a target in dopamine-resistant prolactinomas?Frontiers in endocrinology · 2022Review
- Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.Frontiers in endocrinology · 2021Review
- Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists.Frontiers in endocrinology · 2021Article
- Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively.Cell death & disease · 2019Article
- The MAPK Pathway-Based Drug Therapeutic Targets in Pituitary Adenomas.Frontiers in endocrinology · 2019Review
- The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas.Frontiers in endocrinology · 2018Review
- Activation of DRD5 (dopamine receptor D5) inhibits tumor growth by autophagic cell death.Autophagy · 2017Article
- Suppression of mTOR pathway and induction of autophagy-dependent cell death by cabergoline.Oncotarget · 2015Article
- Dopamine modulates insulin release and is involved in the survival of rat pancreatic beta cells.PloS one · 2015Article
- Roles of dopamine receptors and their antagonist thioridazine in hepatoma metastasis.OncoTargets and therapy · 2015Article
- Antiapoptotic factor humanin is expressed in normal and tumoral pituitary cells and protects them from TNF-α-induced apoptosis.PloS one · 2014Article
- Article
- Each individual isoform of the dopamine D2 receptor protects from lactotroph hyperplasia.Molecular endocrinology (Baltimore, Md.) · 2013Article
- Nerve growth factor, D2 receptor isoforms, and pituitary tumors.Endocrine · 2012Article
- Differential effects of nerve growth factor on expression of dopamine 2 receptor subtypes in GH3 rat pituitary tumor cells.Endocrine · 2012Article
- CEBPD suppresses prolactin expression and prolactinoma cell proliferation.Molecular endocrinology (Baltimore, Md.) · 2011Article
- Protective role of taurine against morphine-induced neurotoxicity in C6 cells via inhibition of oxidative stress.Neurotoxicity research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Dopamine, through D2 receptor (D2R), is the major regulator of lactotrope function in the anterior pituitary gland. Both D2R isoforms, long (D2L) and short (D2S), are expressed in lactotropes. Although both isoforms can transduce dopamine signal, they differ in the mechanism that leads to cell response. The administration of D2R agonists, such as cabergoline, is the main pharmacological treatment for prolactinomas, but resistance to these drugs exists, which has been associated with alterations in D2R expression. We previously reported that dopamine and cabergoline induce apoptosis of lactotropes in primary culture in an estrogen-dependent manner. In this study we used an in vivo model to confirm the permissive action of estradiol in the apoptosis of anterior pituitary cells induced by D2R agonists. Administration of cabergoline to female rats induced apoptosis, measured by Annexin-V staining, in anterior pituitary gland from estradiol-treated rats but not from ovariectomized rats. To evaluate the participation of D2R isoforms in the apoptosis induced by dopamine we used lactotrope-derived PR1 cells stably transfected with expression vectors encoding D2L or D2S receptors. In the presence of estradiol, dopamine induced apoptosis, determined by ELISA and TUNEL assay, only in PR1-D2S cells. To study the role of p38 MAPK in apoptosis induced by D2R activation, anterior pituitary cells from primary culture or PR1-D2S were incubated with an inhibitor of the p38 MAPK pathway (SB203850). SB203580 blocked the apoptotic effect of D2R activation in lactotropes from primary cultures and PR1-D2S cells. Dopamine also induced p38 MAPK phosphorylation, determined by western blot, in PR1-D2S cells and estradiol enhanced this effect. These data suggest that, in the presence of estradiol, D2R agonists induce apoptosis of lactotropes by their interaction with D2S receptors and that p38 MAPK is involved in this process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.